Methodology and definitions
Metabolic outcomes
Evidence
Value
Remarks
Bone outcomes
Evidence
Values
Remarks
Cardiovascular outcomes
Evidence
Values
Remarks
Sexual function
Evidence
Values
Remarks
Other outcomes
Evidence
Depression
Characteristics of study population | Outcome | Number of available RCTs | Number of enrolled subjects | Mean duration of RCT months (range) | Summary of observed effects |
---|---|---|---|---|---|
MetS or T2DM | Waist circumference | 6 | 701 | 10.7 [2.7–24] | ↓ |
Metabolically unclassified | Waist circumference | 3 | 172 | 6.6 [3–11] | ↔ |
MetS or T2DM | BMI | 8 | 773 | 8.8 [2.7–24] | ↔ |
Metabolically unclassified | BMI | 5 | 307 | 11.2 [3–24] | ↔ |
MetS or T2DM | Body fat | 5 | 379 | 10.7 [3–24] | ↓ |
Metabolically unclassified | Body fat | 10 | 1,513 | 11 [3–36] | ↓ |
MetS or T2DM | Body lean | 4 | 174 | 10.4 [2.7–24] | ↑ |
Metabolically unclassified | Body lean | 9 | 1,491 | 10.8 [3–36] | ↑ |
MetS or T2DM | Glycaemia | 7 | 725 | 9.6 [2.7–24] | ↔ |
Metabolically unclassified | Glycaemia | 5 | 324 | 9.4 [3–24] | ↔ |
MetS or T2DM | Glycated haemoglobin | 6 | 555 | 10 [2.7–24] | ↓ |
MetS or T2DM | Total cholesterol | 7 | 725 | 9.6 [2.7–24] | ↔ |
Metabolically unclassified | Total cholesterol | 9 | 490 | 11.7 [1–36] | ↓ |
MetS or T2DM | HDL cholesterol | 7 | 725 | 9.6 [2.7–24] | ↔ |
Metabolically unclassified | HDL cholesterol | 10 | 546 | 13 [1–36] | ↔ |
MetS or T2DM | LDL cholesterol | 5 | 633 | 6.2 [2.7–12] | ↔ |
Metabolically unclassified | LDL cholesterol | 8 | 464 | 15.5 [1–36] | ↓ |
MetS or T2DM | Triglycerides | 7 | 725 | 9.6 [2.7–24] | ↔ |
Metabolically unclassified | Triglycerides | 8 | 380 | 8.7 [1–36] | ↓ |
Healthy men | Lumbar and femoral bone mineral density | 2 | 41 | 12–36 | ↑ lumbar ↑ femoral |
History of fracture or T-score <−2.0 and frailty | Lumbar, femoral and radius bone mineral density | 1 | 53 | 12 | ↑ lumbar ↓ radius |
Young to middle-aged men with sexual dysfunction | Libido | 17 | 1,111 | 3 months (1–12) | ↑ (if T < 8 nM/L) |
Young to middle-aged men with sexual dysfunction | Sexual related erections | 24 | 1,431 | 3 months (1–12) | ↑ (if T < 12 nM/L) |
Young to middle-aged men with sexual dysfunction | Orgasmic function | 10 | 677 | 3 months (1–12) | ↑ (if T < 12 nM/L) |
Middle-aged to aged men with hypogonadism | Serum PSA | 6 | 286 | 16.5 [3–36] | ↔ |
Men with hypogonadism (unspecified age or wide age range) | Serum PSA | 10 | 461 | 6 [3–12] | ↔ |
Middle-aged men with hypogonadism | Prostate volume or prostate-related symptoms (DRE and evaluation of low urinary tract function) | 7 | 256 | 10 [3–36] | ↔ |
Men with hypogonadism and prostate cancer | Serum PSA, prostate volume or symptoms (urine flow rate, voiding symptoms, prostate biopsy) | 1 | 21 | 6 | ↔ |
Men with hypogonadism and diabetes mellitus type 2 or Metabolic syndrome | Serum PSA, Prostate volume, IPSS | 3 | 239 | 10 [7–12] | ↔ |
Major depression | Improvement of depressive symptoms | 5 | 210 | 7.6 (6–12) | ↑ |
HIV/AIDS | Improvement of lean mass | 2 | 82 | 21 (16–26) | ↑ |